BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

160 related articles for article (PubMed ID: 38283321)

  • 1. Analytical assessment and validation of the ProteinSimple ELLA serum B-cell maturation antigen assay.
    Kirchhoff DC; Zhang W; Chandras A; Mendu DR
    Pract Lab Med; 2024 Jan; 38():e00354. PubMed ID: 38283321
    [TBL] [Abstract][Full Text] [Related]  

  • 2. sBCMA Plasma Level Dynamics and Anti-BCMA CAR-T-Cell Treatment in Relapsed Multiple Myeloma.
    Seipel K; Porret N; Wiedemann G; Jeker B; Bacher VU; Pabst T
    Curr Issues Mol Biol; 2022 Mar; 44(4):1463-1471. PubMed ID: 35723356
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Soluble B-cell maturation antigen as a monitoring marker for multiple myeloma.
    Wiedemann Á; Szita VR; Horváth R; Szederjesi A; Sebő A; Tóth AD; Masszi T; Varga G
    Pathol Oncol Res; 2023; 29():1611171. PubMed ID: 37188125
    [No Abstract]   [Full Text] [Related]  

  • 4. Addressing soluble target interference in the development of a functional assay for the detection of neutralizing antibodies against a BCMA-CD3 bispecific antibody.
    Wang Y; Luong M; Guadiz C; Zhang M; Gorovits B
    J Immunol Methods; 2019 Nov; 474():112642. PubMed ID: 31400410
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Deciphering the Exact Sequence of Endogenous Soluble B Cell Maturation Antigen and Unbiased Quantitation in Multiple Myeloma Patient Samples by LC-MS.
    Shen X; Dong X; Shi J; Chen H; Lan Y; Lim AC; Xie F; Ang A; Kratzer A; Rock DA; Rock BM
    Clin Chem; 2024 Jan; 70(1):339-349. PubMed ID: 38175591
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Elevated serum levels of soluble B-cell maturation antigen as a prognostic biomarker for multiple myeloma.
    Guo P; Wang Y; He H; Chen D; Liu J; Qiang W; Lu J; Liang Y; Du J
    Clin Exp Immunol; 2024 May; ():. PubMed ID: 38743453
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Soluble TACI and soluble BCMA as biomarkers in primary central nervous system lymphoma.
    Thaler FS; Laurent SA; Huber M; Mulazzani M; Dreyling M; Ködel U; Kümpfel T; Straube A; Meinl E; von Baumgarten L
    Neuro Oncol; 2017 Nov; 19(12):1618-1627. PubMed ID: 28521029
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Serum BCMA levels predict outcomes in MGUS and smoldering myeloma patients.
    Visram A; Soof C; Rajkumar SV; Kumar SK; Bujarski S; Spektor TM; Kyle RA; Berenson JR; Dispenzieri A
    Blood Cancer J; 2021 Jun; 11(6):120. PubMed ID: 34168119
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Serum B-Cell Maturation Antigen (BCMA) Levels Differentiate Primary Antibody Deficiencies.
    Maglione PJ; Ko HM; Tokuyama M; Gyimesi G; Soof C; Li M; Sanchez E; Chen H; Radigan L; Berenson J; Cunningham-Rundles C
    J Allergy Clin Immunol Pract; 2020 Jan; 8(1):283-291.e1. PubMed ID: 31430592
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Baseline and Changes in Serum B-Cell Maturation Antigen Levels Rapidly Indicate Changes in Clinical Status Among Patients with Relapsed/Refractory Multiple Myeloma Starting New Therapy.
    Bujarski S; Udd K; Soof C; Chen H; Spektor TM; Safaie T; Li M; Stern J; Wang C; Xu N; Emamy-Sadr M; Swift R; Rahbari A; Patil S; Souther E; Regidor B; Sutanto C; Berenson JR
    Target Oncol; 2021 Jul; 16(4):503-515. PubMed ID: 34097243
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Baseline serum B-cell maturation antigen levels predict time to disease progression for patients with smoldering multiple myeloma.
    Bujarski S; Goldwater MS; Regidor BS; Jew S; Daniely D; Swift RA; Eades BM; Emamy-Sadr M; Souther E; Li M; Wang C; Xu N; Chen H; Spektor TM; Berenson JR
    Eur J Haematol; 2021 Sep; 107(3):318-323. PubMed ID: 33993536
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Serum B-Cell maturation antigen is an independent prognostic marker in previously untreated chronic lymphocytic leukemia.
    Soof CM; Spektor TM; Parikh SA; Slager SL; Rabe KG; Call TG; Kenderian SS; Ding W; Muchtar E; Ghermezi M; Kay NE; Berenson JR
    Exp Hematol; 2022 Jul; 111():32-40. PubMed ID: 35525334
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [The expression level of secretory mature B cell surface antigen in primary diagnosed multiple myeloma and its clinical significance].
    Yan Z; Chen GH; Yao WQ; Yan LZ; Jin S; Shang JJ; Shi XL; Wu DP; Fu CC
    Zhonghua Yi Xue Za Zhi; 2022 Aug; 102(30):2351-2356. PubMed ID: 35970793
    [No Abstract]   [Full Text] [Related]  

  • 14. Analysis of the receptor BCMA as a biomarker in systemic lupus erythematosus patients.
    Salazar-Camarena DC; Palafox-Sánchez CA; Cruz A; Marín-Rosales M; Muñoz-Valle JF
    Sci Rep; 2020 Apr; 10(1):6236. PubMed ID: 32277232
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The role of soluble B cell maturation antigen as a biomarker in multiple myeloma.
    Alomari M; Kunacheewa C; Manasanch EE
    Leuk Lymphoma; 2023 Feb; 64(2):261-272. PubMed ID: 36282671
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Use of serum B-cell maturation antigen levels to predict outcomes for myeloma patients treated with ruxolitinib, lenalidomide and methylprednisolone.
    Bujarski S; Sutanto C; Spektor TM; To J; Swift RA; Green T; Eades BR; Emamy-Sadr M; Souther E; Berenson JR
    Hematol Oncol; 2022 Apr; 40(2):243-248. PubMed ID: 34982491
    [TBL] [Abstract][Full Text] [Related]  

  • 17. γ-Secretase inhibition increases efficacy of BCMA-specific chimeric antigen receptor T cells in multiple myeloma.
    Pont MJ; Hill T; Cole GO; Abbott JJ; Kelliher J; Salter AI; Hudecek M; Comstock ML; Rajan A; Patel BKR; Voutsinas JM; Wu Q; Liu L; Cowan AJ; Wood BL; Green DJ; Riddell SR
    Blood; 2019 Nov; 134(19):1585-1597. PubMed ID: 31558469
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Expression of sBCMA in Newly Diagnosed Multiple Myeloma Patients and Its Relationship with Prognosis].
    Zheng LL; Li B
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2023 Aug; 31(4):1108-1112. PubMed ID: 37551484
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The Role of B-Cell Maturation Antigen in the Biology and Management of, and as a Potential Therapeutic Target in, Multiple Myeloma.
    Sanchez E; Smith EJ; Yashar MA; Patil S; Li M; Porter AL; Tanenbaum EJ; Schlossberg RE; Soof CM; Hekmati T; Tang G; Wang CS; Chen H; Berenson JR
    Target Oncol; 2018 Feb; 13(1):39-47. PubMed ID: 29230672
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Serum levels and significance of soluble B-cell maturation antigen in childhood-onset systemic lupus erythematosus with renal involvement.
    Lin Z; Yu N; Cheng C; Jin B; Zhang Q; Zhuang H; Jiang X
    Lupus; 2023 Apr; 32(5):680-687. PubMed ID: 36914971
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.